MARKET

CBIO

CBIO

Catalyst Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.740
-0.070
-1.46%
After Hours: 4.620 -0.12 -2.53% 16:44 04/16 EDT
OPEN
4.830
PREV CLOSE
4.810
HIGH
4.840
LOW
4.610
VOLUME
239.96K
TURNOVER
--
52 WEEK HIGH
8.22
52 WEEK LOW
4.050
MARKET CAP
148.51M
P/E (TTM)
-1.6791
1D
5D
1M
3M
1Y
5Y
Global Hemophilia A Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Hemophilia A Drug market report provides a detailed analysis of global market size, regional and country-level market...
Heraldkeepers · 3d ago
Brassylic Acid Market : How can businesses scope with COVID-19? | Keyplayers : Cathay Industrial Biotech, Palmary Chemical, Unisource Chemicals Pvt. Ltd.
Apr 15, 2021 (Market Insight Reports) -- Brassylic acid is a versatile chemical intermediate. Brassylic acid was first created in the nineteenth century...
Market Insight Reports · 3d ago
Haemophilia Market 2021 to 2025 Product, Distribution Channel, Region, Forecast and Opportunities during Ongoing COVID-19 Pandemic
Apr 15, 2021 (AmericaNewsHour) -- Kenneth Research recently added a report on 'Haemophilia Market ' in its database of market research reports which provides...
AmericaNewsHour · 3d ago
Catalyst Biosciences Says Expands Protease Medicines Patent Portfolio Of Complement Factor 3 Degraders
Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 10,954,501 B2 entitled "Nucleic Acid Encoding Modified Membrane Type
Benzinga · 6d ago
Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
GlobeNewswire · 04/07 21:05
Hemophilia A Drug Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Apr 05, 2021 (Market Insight Reports) -- The latest report as Hemophilia A Drug Market acknowledges Size, Application Segment, Type, Regional Outlook, Market...
Market Insight Reports · 04/05 16:48
Haemophilia Treatment Market Research Considering SWOT Analysis, Market Risk, Growth Opportunities, Challenges and Regional Analytics- Market.Biz
Haemophilia Treatment Market Size-Share Analysis Apr 05, 2021 (WiredRelease via Comtex) -- The global Haemophilia Treatment marketsize is projected to gain...
marketresearch.biz · 04/05 05:26
Hemophilia A Drug Market Size 2021- Covid-19 Impact Analysis by Sales Revenue, Market Dynamics with Top Players, Development Plans and Demand Status Forecast to 2025
Apr 01, 2021 (The Expresswire) -- The "Hemophilia A Drug Market" research report presents an in-depth assessment of trends affecting industry dynamics with...
The Express Wire · 04/01 07:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBIO. Analyze the recent business situations of Catalyst Biosciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBIO stock price target is 17.80 with a high estimate of 25.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 121
Institutional Holdings: 16.49M
% Owned: 52.62%
Shares Outstanding: 31.33M
TypeInstitutionsShares
Increased
31
892.77K
New
18
1.50M
Decreased
18
1.29M
Sold Out
14
789.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Augustine Lawlor
President/Chief Executive Officer/Director
Nassim Usman
Chief Financial Officer
Clinton Musil
Senior Vice President
Charles Democko
Other
Howard Levy
Vice President
Arwa Shurrab
Independent Director
Errol De Souza
Independent Director
Andrea Hunt
Other
Jamie Siegel
Independent Director
Geoffrey Ling
Independent Director
Sharon Tetlow
Independent Director
Edward Williams
Independent Director
Fei Ling Shiu
Declaration Date
Dividend Per Share
Ex-Div Date
08/04/2015
Dividend USD 0.5692
08/20/2015
  • All
  • Financials
  • Insiders
More
About CBIO
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Webull offers kinds of Catalyst Biosciences Inc stock information, including NASDAQ:CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.